4C Medical Technologies

4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR). We are the first transcatheter MR therapy that directly addresses mitral regurgitation without replacing the native mitral valve, thus preserving the native mitral annulus and left ventricle.

Katherine Kumar, Executive Vice President
kkumar@4CMed.com
+1-612-716-5578
www.4CMed.com

AFFLUENT MEDICAL

AFFLUENT MEDICAL is a medical device company which has developed innovative implants for minimally invasive and transcatheter surgery in the cardiovascular and urology fields. Its structural-heart franchise includes notably technologies for mitral valve repair and replacement, which are now either in clinical or advanced preclinical validation phase. Incorporated in 2018, AFFLUENT MEDICAL integrates product developments mostly started in 2011/2012. CE mark for its first product is expected in 2020/2021. The company headquarter is in France and it has research and technical facilities in France and Italy. It has a workforce of above 30 people, about 80% dedicated to R&D.

Daniele Zanotti, AFFLUENT MEDICAL CEO
daniele@affluentmedical.com
tel. +33 7 84085829
www.affluentmedical.com

AuriGen Medical

AuriGen Medical is an electrophysiology and structural heart company, developing the next generation of LAA implant to treat both the stroke and arrhythmia risk associated with persistent atrial fibrillation. The AuriGen device will be a fast single shot option to permanently electrically isolate and occlude the LAA. The technology incorporates real time sensor confirmation of permanent electrical isolation, without the need for complex mapping. (This is an investigation device and not approved for human use)

Dr John Thompson, CEO and co-founder
John.Thompson@AuriGenMedical.com
+353 86 352 5057
www.aurigenmedical.com

BIOMODEX

Paris & Boston based BIOMODEX is using advanced software and 3D printers to fabricate life-like organs that can be used for interventional training and pre-operative planning in the INR and structural heart disease spaces.Using data obtained through imaging (CT or Echo), BIOMODEX developed a process that helps automate the creation of a virtual 3D model of that organ, which can then be printed using a 3D printer. The INVIVOTECH unique biomechanics technology allows fabricating an organ that behaves the same than the organ of the specific patient, including the surrounding tissues. Their invention will help improve interventional procedures safety by enabling physicians to acquire knowledge and patient-specific experience without putting patients at risk.

Thomas MARCHAND, CEO & Co-Founder
thomasmarchand@biomodex.com
+1 (617) 691 77 39
www.biomodex.com

CardioCorX

CardioCorX is venture capital funded start-up incorporated in Europe with a US subsidiary. We are an innovative medical device company committed to transforming the lives of millions of patients effected by atrial fibrillation (AF), patients at risk of stroke and patients with Heart Failure (HF) and AF. By developing a minimally invasive cardiac catheter based technology providing Physicians with a portfolio of unique-to-market dual platform breakthrough product that electrically isolate the Left-Atrial Appendage(LAA) eliminating the arrhythmogenic sources coming from the LAA, prevent blood clots forming in the LAA which could lead to stroke and them to record, monitor for real-time Left-Atrial Pressure (LAP) for HF patient management and ECGs for continues AF management.

Randy Werneth
Randy@cardiocorx.com

Cardiologs

Cardiologs develops a cloud-based platform, powered by medical-grade artificial intelligence, for massive heart screening. Cardiologs is currently focused on solving ECG diagnostics. Leveraging on cutting-edge machine learning technology and a proprietary database of 600,000 cases (and counting), we develop and commercialize a cloud-based platform to solve ECG analysis. Cardiologs has been the first deep-learning enabled medical device approved for commercialisation in Europe in August 2016, and has been cleared by the FDA in June 2017.

Yann Fleureau, CEO
yann@cardiologs.com

CARMAT

The Total Artificial Heart is an Advanced Heart Failure therapy answering an important untapped need. More and more patients are affected by heart failure and cost to society is growing exponentially. The Carmat Heart is the first and most advanced bioprosthetic autoregulated technology. It is the only technology addressing ventricules, hemocompatibility and pulsatility altogether. The level of acceptance among scientific communities is very high. The First in Man has been achieved with success. 6 patients of the CE mark trial has been enrolled. Discussions with FDA are on going. CARMAT is THE Ground Breaking Innovation for end-stage biventricular Heart Failure.

Stéphane Piat, Chief Executive Officer
stephane.piat@carmatsas.com

www.carmatsa.com

CorFlow Therapeutics

CorFlow Therapeutics AG addresses a large unmet need in interventional cardiology: microvascular obstruction (MVO) in heart attack patients. MVO is a predictor of death and heart failure in these patients.
The company has developed the Controlled Flow Infusion (CoFI™) system which enables measurement of the microvascular status in the cathlab after stent placement. The platform also enables treatment of MVO and the company has filed IP to protect its technology.
CorFlow is founded by Prof. Martin Rothman, Dr. Rob Schwartz and Jon Hoem who all have a lifelong dedication to medical device innovation.
The company will initiate its first-in-man clinical trial in 2018 and has raised CHF 7.5M to execute its plans.

Jon H. Hoem
jhoem@corflow-therapeutics.ch
+41 41 544 55 55

www.corflow-therapeutics.ch

Elixir Medical Corporation

Elixir Medical Corporation was founded in 2005 to develop innovative products that combine state-of-the-art technology with advanced pharmaceuticals to provide innovative drug-device treatment solutions to patients worldwide

Motasim Sirhan, CEO
msirhan@elixirmedical.com
408-636-2011
www.elixirmedical.com

Endotronix

Endotronix, Inc., a medical technology company, is developing an integrated platform to provide comprehensive, reimbursable health management innovations for patients suffering from advanced heart failure. The company's solution, the Cordella™ Heart Failure System, includes a cloud-based disease management data system and at home hemodynamic management with a breakthrough implantable wireless pulmonary artery pressure sensor for early detection of worsening heart failure.

Harry Rowland, CEO
harry.rowland@endotronix.com
www.endotronix.com.

FEops

FEops is a leader in personalized computational modeling and simulation for structural heart interventions. Backed by strong preclinical data, FEops HEARTguideTM presents a prime opportunity to integrate transcatheter structural heart device design with patient-specific testing, and to do so virtually, cost-effectively and in a clinically meaningful way. Showcasing a pipeline of simulation products for structural heart, including TAVI, mitral and tricuspid valve replacement, and LAAO, FEops has the ambition to enable wider adoption of transcatheter approaches by minimizing the risk of life-threatening complications while reducing cost, and thus improve patient care.

Matthieu De Beule, CEO
matthieu.debeule@feops.com
+32 474 23 86 98
feops.com

G3 - Global Genomics Group

G3, or Global Genomics Group, is a precision-medicine based biopharma company, discovering, validating and developing novel drugs based on biological Big Data. G3 assembled one of the largest "panomic" dataset in the world. G3 prospectively enrolled nearly 8,000 patients in their GLOBAL clinical study and evaluated a number of important disease states quantitatively with our imaging modalities. This imaging/phenotyping data is coupled with an extensive panomic molecular profiling analysis, including whole genome sequencing, DNA methylation, RNA sequencing (mRNA and miR), proteomics, metabolomics, lipidomics, etc. G3 has participated in publications in journals such as the Nature family of journals, as well as the New England Journal of Medicine. G3 has identified and patented blood-based diagnostic biomarkers and identified and genetically validated a novel target for NASH (non-alcoholic steatohepatitis) and coronary artery disease.

Szilard Voros, CEO
Szilard.voros@globalgenomicsgroup.com
678-459-5682

HARTLON

HARTLON (https://hartlon.com) produces the HARTSORB™ bioresorbable scaffold (BRS), which is the only BRS that delivers a drug until the mass of the scaffold is no longer present within the treatment site. The scaffold has a dual drug delivery mechanism, wherein the first drug delivery manages the local tissue response to the injury imparted on the arterial tissue and the second drug delivery manages the arterial tissue response to the acidic environment created during resorption. The patented scaffold manufacturing process positions the drug within the scaffold's multilayer wall thickness so that the drug is slowly released over time. Jack Scanlon is the founder of HARTLON and is in the process of forming a Delaware (USA) corporation.

For inquiries, please write to info.hartlon@gmail.com

HealthWatch

HealthWatch Technologies is a sensor and analytics innovative medical device technology company. HealthWatch's innovative textile medical sensor technology and its in-depth patient management system, has wide market applications both within and outside the hospital environs. Our Master Caution® patented platform technology is the first and only 12-lead ECG smart digital garment that is CE/FDA cleared and is the answer to the growing paradigm shift within the healthcare ecosystem. The Master Caution® is ideal for use in hospitals, post cardiac events patients at home, post stroke patients, cardiac rehabilitation centers or for general health and peace of mind all without adhesives, skin preparations or changing ones' day-to-day behavior.

Israel Schrieber, CEO
+972-9-7677039
info@healthwatchtech.com
www.healthwatchtech.com

InnoRa

InnoRa is focused on development and manufacture of intravascular catheters and stents, including drug coated balloon catheters and stents. Main services are contract development and production in the field of non-active implants and catheters. InnoRa can cover the whole medical device development process from first ideas up to clinical trials, approval/ certification support and pilot production. Attention is turned to a lean, rapid and cost effective development process. InnoRa's technology is backed by broad patent protection and awarded with two innovation awards. The company is EN ISO 13485:2016 certified.

Thomas Speck, CEO
thomas.speck@innora.de
+49 30 85 74 117-17
www.innora.de

Japan Medical Device Technology

We have focused on research and development of coronary stent for about 15 years.
Our current R&D base is in Research Park operated by Kumamoto prefecture.
We have set a goal for establishing basic technology on bioabsorbable stent(excellent radial force with thin strut(100μm), small area ratio(<20%) and so on) of new Mg alloy for coronary arteries and undertaking non-clinical test based on GLP standard. We began searching for a medical device manufacturing company that is interested in jointly commercializing this product.

Shuzo Yamashita, President
Yamshita.nora@mbr.nifty.com
+81-96-285-8278
www.jmdt.co.jp

Magenta Medical

Magenta Medical Ltd. – Device Solutions for Acute Heart Failure
Magenta has developed a temporary venous catheter-based therapy for hospital-admitted patients with acute decompensated heart failure. Its therapeutic principle is aimed at addressing renal venous congestion and its deleterious effects on renal and cardiac function.
The experimental animal data with the system is compelling and in line with a vast and growing body of clinical and experimental evidence supporting the therapeutic concept.
The company is currently conducting human clinical trials and further developing its product portfolio to also address the cardiogenic shock patient population.

David Israeli, CEO
david@magentamed.com
+972-52-267-2394
www.magentamed.com

Meril

Meril is a global medical device company present in more than 145 countries. The company has clinically relevant, state-of-the-art and best-in-class devices/technologies ranging broad operational canvas viz- vascular interventions; orthopaedics; endo-surgery and IVD.
Meril CardioVascular has been dedicated to the design & development of novel interventional technologies from DES, BRS, THV & beyond.
BioMime – SES has been a successful concept in new generation DES with low injury design
BioMime Morph – SES, is a CE marked unique tapered stent with lengths up to 60mm
MeRes100 – Sirolimus Eluting BRS is a next generation BRS with 100μm strut thickness
MyVal – Balloon expandable THV with a unique hybrid honey-comb design cell structure & recommended to be crimped directly on Navigator THV delivery system.

Sanjeev Bhatt, Vice President – Corporate Strategy
sanjeev.bhatt@merillife.com
+91 98202 98368

Micro Interventional Devices

Micro Interventional Devices, Inc. (MID) designs, develops and commercializes proprietary soft-tissue anchoring technologies that enable minimally invasive and percutaneous structural heart disease procedures including mitral and tricuspid valve repair and replacement. The company is currently enrolling patients in the STTAR, Study of Transcatheter Tricuspid Annular Repair, clinical study in the EU. MID's soft-tissue PolyCor anchoring technology has been clinically validated in the company's CE Marked and FDA Cleared-to-Market Permaseal transapical access and closure device.

Michael Whitman, President & CEO
info@microinterventional.com
215 600 1270
www.microinterventional.com

NewMed Medical

NewMed Medical Co., Ltd. is a high-tech medical enterprise which was established in March 2015 and located in Shanghai Medical valley PLUS, Zhoupu Town, Pudong District, Shanghai. The company dedicated his work to research, develop, manufacture and market advanced interventional artificial heart valve systems (Including developing transcatheter mitral valve replacement and aortic valve replacement devices). The company always adheres to the common beliefs of profession, safe and efficiency. The company have excellent teams of researchers, engineers, quality assurers and marketers who are willing to climb the medical peak and write a new chapter in the interventional treatment of cardiac valve together with excellent experts in the field of cardiovascular medicine in China. NewMed takes "Innovation improve life" as a purpose. More innovative medical products will be developed to fulfill domestic products and technologies for the benefits of patients.

Qifeng Yu, CEO
qfyu@newmed.cn.
(86)-21-2078 8668
www.newmed.cn

New Valve Technology

New Valve Technology (NVT AG, Muri, Switzerland) is dedicated to developing and marketing innovative technologies for the minimally invasive treatment of all heart valves.
Together with physicians and medical institutions, we pioneer safe and cost-effective therapies. Our long-term corporate view is founded on skilled engineering, fully integrated in-house production and quality at the highest level. Our vision is to help people with valvular heart disease live a healthier and more fulfilling life. With the current CE marked ALLEGRA Transcatheter Aortic Valve Implantation System, New Valve Technology offers a self-expanding valve with new capabilities for an easy, precise and controlled valve implantation

Udo Scheiner, CEO
www.nvt-med.com
info@nvt-med.com
+49(0) 7471 989 79-0

Paragate Medical

Paragate Medical is an innovative med-tech company, addressing one of the greatest unmet needs in healthcare nowadays: a solution for the chronically fluid overloaded and diuretic resistant patients.
Paragate is aiming to revolutionise the heart failure management by introducing a truly out-of-hospital solution to actively and continuously prevent congestion and keep patient balanced.
The minimally invasive device is fully implantable, yet adjustable, enabling moderate and regulated removal of systemic fluids from the tissues to the urinary system, without interfacing circulation and independently of the kidneys.

Nitai Hanani, CEO
info@paragate-medical.com
+972.4.609.8600
www.paragate-medical.com

Philips

Philips: Enabling better health and better care at lower cost
Philips is a leading health technology company focused on improving people's lives across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people's health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics, consumer health and home care.

Frans van Houten, CEO
+31 20 59 77777
www.philips.com

Pi-Cardia

Pi-Cardia is a global leader in the development of unique non-implant based solutions for treating valve calcification. Our Leaflex™ catheter is easily delivered and positioned on the valve, to then mechanically score the calcification at multiple locations, improving leaflets flexibility. The company recently started its First-in-Human study with the device demonstrating safety and hemodynamic improvement, which is significantly superior to that achieved with balloon valvuloplasty. Once clinical safety and efficacy is demonstrated, the Leaflex™ catheter could be used both as a cost-effective standalone treatment, and as a preparatory step for improving the outcome of valve implantation in bicuspid, heavily calcified aortic or mitral valves.

Erez Golan, CEO
erez@pi-cardia.net
+972-8-9484800

POSTECH and T&R Biofab

POSTECH (Pohang Univ. of Science and Technology), M.E. IMS lab (ims.postech.ac.kr, 82-54-279-5889)
Supervisor: Dong-Woo Cho (dwcho@postech.ac.kr),
Presenter: Dong-Heon Ha (dhha88@postech.ac.kr, 82-10-9466-6326)
Co-worked with Prof. Han-Cheol Lee (Pusan National Univ. Hospital, Dept. of Cardiology, glaraone@hanmail.net) and T&R Biofab.

Won-Soo Yun, CEO
wsyun@tnrbiofab.com
tnrbiofab.com

Procyrion

Procyrion is developing Aortix™, a catheter-deployed pump for the ambulatory treatment of heart failure (HF). Procyrion is initially focused on providing treatment for diuretic-resistant acutely decompensated HF.
Aortix both unloads the heart and directly perfuses the kidneys, potentially providing broad clinical utility for millions of patients per year. The intra-aortic placement downstream of the carotid arteries also effectively eliminates risk of thrombotic stroke and aortic valve damage.
In a First-in-Human study, Aortix increased urine output in patients with mild renal dysfunction by a factor of 10 on average (n=4). This implies potential benefit for acutely decompensated HF patients who have few other options.

Benjamin Hertzog, CEO
ben@procyrion.com
+1-713-504-7678
www.procyrion.com

S-Bahn Medical

S-Bahn Medical is a Scottish-based start-up developing a 3rd generation bioresorbable vascular scaffold (BVS). Their patent pending, hybrid BVS design utilizes both metal and polymer structural components, differentiating it from active BVS in trials. S-Bahn Medical hybrid technology addresses the underlying shortcomings of earlier generations of BVS to advance this promising technology.

Calum MacLeod, Mechanical Engineer

cbmacleod@s-bahnmedical.com

Sequana Medical

We are a commercial stage medical device company and an innovator in the management of liver disease, heart failure and other fluid management disorders. Our Direct Sodium Removal (DSR) therapy for the treatment of fluid overload in heart failure has demonstrated efficacy and safety in large animal studies. DSR therapy leverages the unique capabilities of our clinically proven alfapump®, a fully implantable, programmable, transcutaneously-charged, battery-powered pump. Our DirectLink Technology allows clinicians to monitor the alfapump® and delivers important insights. The alfapump® is CE-marked for the management of refractory ascites and the interim results of the MOSAIC IDE pilot study were presented at AASLD 2017.

Ian Crosbie, CEO
ian.crosbie@sequanamedical.com
www.sequanamedical.com

ShockWave Medical

Shockwave Medical is developing and commercialising innovative intravascular lithotripsy (IVL) technology for the treatment of calcified peripheral vascular, coronary vascular and heart valve disease. IVL leverages similar principles to urologic lithotripsy, which has been used as a safe and effective treatment for kidney stones for several decades. Shockwave's generator produces energy that travels through the catheter to an array of miniaturized lithotripsy emitters once per second. When activated, a small electrical discharge at the emitters vaporizes the fluid within the catheter and creates a rapidly expanding bubble that collapses within microseconds. The bubble's collapse generates a series of sonic pressure waves that pass through soft tissue, selectively cracking the hardened calcified plaque.

For more information, visit www.shockwavemedical.com

Stentit

Stentit is a young medical device company based in Eindhoven dedicated to the development and production of minimally-invasive vascular implants. Stentit's bioabsorbable fibrous grafts are intended to provide support to the artery upon deployment, while triggering the patient's immune response to promote a spontaneous regenerative response. In this way, the patient's own cells are able to produce new vascular tissue that gradually replaces the implant over time.

Sol Cabrera, s.cabrera@stentit.com,
Bart Sanders, b.sanders@stentit.com,
Co-Founders and Directors
www.stentit.com
0031(0)402472445

IBM Watson

IBM is an American technologycompany headquartered in Armonk with operations in over 170 countries. IBM is led by its CEO Virginia Marie "Ginni" Rometty. IBM creates and delivers the most leading technology, enabled by artificial intelligence (AI), analytics, and cloud computing. IBM Watson provides a portfolio of AI solutions and services available in the IBM Cloud. Current applications of Watson solutions in the life sciences sector include cardiology, medical image analysis, drug discovery, genomics and oncology. IBM delivers cognitive medical imaging solutions for radiologists, cardiologists who treat a wide variety of diseases.

Annika Grosse
IBM Executive Partner, Global Business Services
Watson Health Practice Leader, Europe
annika.grosse@de.ibm.com
+49-40-6389-1122

Xeltis

Xeltis is a clinical-stage medical device company developing the first heart valves that enable the patient's own body to naturally restore a new heart valve through a therapeutic approach called Endogenous Tissue Restoration (ETR). With ETR, the patient's natural healing system develops tissue that pervades Xeltis' heart valve, forming a new, natural and fully functional valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body. The first feasibility clinical trial for Xeltis' pulmonary valve, Xplore-I, is underway in Europe and Asia. An Early Feasibility Study (EFS) in US on Xeltis' pulmonary valve, XPlore-II is now enrolling. Xeltis' aortic valve program is in pre-clinical stage. Data on more than 50 animals in an ovine transapical aortic model show good performance out to 1 year with ongoing ETR.

Laurent Grandidier, CEO
Laurent.grandidier@xeltis.com
www.xeltis.com